| Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised … G Attard, L Murphy, NW Clarke, W Cross, RJ Jones, CC Parker, ... The lancet 399 (10323), 447-460, 2022 | 260 | 2022 |
| Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers EC Page, EK Bancroft, MN Brook, M Assel, MH Al Battat, S Thomas, ... European urology 76 (6), 831-842, 2019 | 227 | 2019 |
| 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial TJ Iveson, RS Kerr, MP Saunders, J Cassidy, NH Hollander, J Tabernero, ... The Lancet Oncology 19 (4), 562-578, 2018 | 202 | 2018 |
| Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma A Hughes, P Calvert, A Azzabi, R Plummer, R Johnson, J Rusthoven, ... Journal of clinical oncology 20 (16), 3533-3544, 2002 | 186 | 2002 |
| A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study EK Bancroft, EC Page, MN Brook, S Thomas, N Taylor, J Pope, J McHugh, ... The Lancet Oncology 22 (11), 1618-1631, 2021 | 67 | 2021 |
| A phase I clinical and pharmacokinetic study of EPO906 (epothilone B), given every three weeks, in patients with advanced solid tumors PM Calvert, V O’neill, C Twelves, A Azzabi, A Hughes, C Bale, ... Proc Am Soc Clin Oncol 20, 108a, 2001 | 65 | 2001 |
| Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) MA Batey, JG Wright, A Azzabi, DR Newell, MJ Lind, AH Calvert, ... European Journal of Cancer 38 (8), 1081-1089, 2002 | 47 | 2002 |
| Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): An open-label, non … JE Brown, KL Royle, W Gregory, C Ralph, A Maraveyas, O Din, T Eisen, ... The Lancet Oncology 24 (3), 213-227, 2023 | 40 | 2023 |
| A phase I study of a novel, trinuclear, platinum analogue, BBR3464, in patients with advanced solid tumors. PM Calvert, MS Highley, AN Hughes, ER Plummer, AST Azzabi, ... Clin Cancer Res 5, 3796S-3796S, 1999 | 40 | 1999 |
| Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two … G Attard, L Murphy, NW Clarke, A Sachdeva, C Jones, A Hoyle, W Cross, ... The Lancet Oncology 24 (5), 443-456, 2023 | 30 | 2023 |
| 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT. T Iveson, KA Boyd, RS Kerr, J Robles-Zurita, MP Saunders, AH Briggs, ... Health Technology Assessment (Winchester, England) 23 (64), 1, 2019 | 27 | 2019 |
| SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer J Robles-Zurita, KA Boyd, AH Briggs, T Iveson, RS Kerr, MP Saunders, ... British journal of cancer 119 (11), 1332-1338, 2018 | 27 | 2018 |
| Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations A Azzabi, AN Hughes, PM Calvert, ER Plummer, R Todd, MJ Griffin, ... British journal of cancer 92 (6), 1006-1012, 2005 | 27 | 2005 |
| Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array EJ Saunders, T Dadaev, DA Leongamornlert, AAA Olama, S Benlloch, ... British journal of cancer 114 (8), 945-952, 2016 | 18 | 2016 |
| Optimising radium 223 therapy for metastatic castration-resistant prostate cancer–5-year real-world outcome: Focusing on treatment sequence and quality of life XY Jiang, S Atkinson, R Pearson, D Leaning, S Cumming, A Burns, ... Clinical Oncology 32 (10), e177-e187, 2020 | 14 | 2020 |
| A phase I dose escalation study of doxorubicin in combination with pemetrexed (Alimta (R), multitargeted antifolate). AN Hughes, M Lind, AS Azzabi, R Todd, ER Plummer, JP Margetts, ... Breast Cancer Research and Treatment, 2001 | 8 | 2001 |
| A phase I clinical and pharmacokinetic study of EPO906 (epothilone B) in patients with advanced solid tumours. PM Calvert, V O'Neill, AS Azzabi, AN Hughes, ER Plummer, C Twelves, ... Clinical Cancer Research, 2000 | 7 | 2000 |
| Tolerability and efficacy of anti-androgen manipulation versus taxotere and anti-androgen manipulation in patients with hormone-naive, high-risk/metastatic prostate cancer: A … ID Pedley, JA Frew, JM Wilson, AR Abdul Razak, A Azzabi, R McMenemin, ... Journal of Clinical Oncology 29 (7_suppl), 147-147, 2011 | 5 | 2011 |
| Evaluation of early response to neoadjuvant chemotherapy in muscle-invasive bladder cancer using dynamic contrast-enhanced MRI and diffusion weighted MRI: MARBLE study. RA Pearson, PE Thelwall, J Snell, J McKenna, P Pieniazek, EL Fitzgerald, ... Journal of Clinical Oncology 34 (2_suppl), 403-403, 2016 | 4 | 2016 |
| Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with … P Rajan, JA Frew, JM Wilson, AST Azzabi, RM McMenemin, J Stockley, ... Urologic Oncology: Seminars and Original Investigations 33 (8), 337. e1-337. e6, 2015 | 4 | 2015 |
naeem soomroProfessor of Urology / Consulant Urologist, Newcastle Hopsitals. Newcastle University, UKVerified email at nhs.net
